Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Details : RHB-107, a proprietary, first-in-class, once-daily orally administered investigational antiviral, is currently undergoing mid-stage clinical trials for treating Covid-19.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (Upamostat) is a serine protease inhibitor small molecule drug candidate, which is currently being evaluated in combination with remdesivir for the treatment of Ebola.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Upamostat,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Henry M. Jackson Foundation
Deal Size : $4.8 million
Deal Type : Funding
Details : The finding aims to support RedHill to focus on the development of RHB-107 (upamostat), a potent inhibitor of serine proteases. It is being evaluated in the treatment of early outpatientand post-exposure prophylaxis for Severe Acute Respiratory Syndrome ...
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Henry M. Jackson Foundation
Deal Size : $4.8 million
Deal Type : Funding
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (Upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Details : Phase 2 part of Phase 2/3 study of RHB-107 (upamostat), orally-administered antiviral, that targets human serine proteases in symptomatic COVID-19 successfully met study's primary endpoint showing good safety, tolerability and highly promising efficacy r...
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated dual anti-inflammatory and antiviral activity, targeting a human cell component involved in viral replication.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : RedHill Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2021
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : RedHill Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in a human bronchial cell model and targets a host cell component involved in viral replication, minimizing potential for resistance due to viral mutations.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : NIAID
Deal Size : Undisclosed
Deal Type : Agreement
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
Details : RedHill Biopharma will provide its investigational drug, RHB-107 (upamostat, WX-671), for testing in non-clinical studies for activity against SARS-CoV-2.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : NIAID
Deal Size : Undisclosed
Deal Type : Agreement